fashion -WSS

fashion

author：explore 2025-09-01 15:15:05 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

This week: A chat with Argenx CEO Tim Van Hauwermeiren, and updates on biotech PIPEs, Madrigal Pharmaceuticals, and Annovis Bio.

The Belgian drugmaker Argenx is preparing for a commercial launch this summer that will expand the use of its IgG-lowering antibody Vyvgart to patients with chronic inflammatory demyelinating polyneuropathy, or CIDP, an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Elevance, SCAN deals highlight health insurer acquisition scrutiny

hotspot

WSS

White House Covid adviser calls on docs to combat misinformation

Hospitals are piloting generative AI tools as regulators play catch

What happened to the House vote on health price transparency?

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Researchers tackle phage therapy hurdles for wider adoption

Medicare Advantage enrollment grows 7.1% to 33.4 million people

hotspot

fashion

entertainment

Heart attack and stroke risk calculators need revising

Ukraine seeks to reclaim its role as a hub for clinical trials

What does generative AI mean for health care? We asked experts

New CMS data security rules will hurt Medicare, Medicaid research

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Elevance, SCAN deals highlight health insurer acquisition scrutiny

How one medical school became remarkably diverse

'A game

23andMe had bad news about my health. I wish a person had delivered it

New CMS data security rules will hurt Medicare, Medicaid research

explore

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Obamacare plans could cover weight loss drugs

Fed up with FDA, ALS advocates consider a take

How the messy conversation about Dolly changed bioethics

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

entertainment

hotspot

leisure time

Wikipedia